Abstract
This study assessed the effectiveness, adverse events, patient adherence, and costs of modified dual therapy compared with bismuth-containing quadruple therapy for treating Helicobacter pylori infection in Chinese patients. We also sought to determine whether modified dual therapy could be used as an alternative first-line treatment for H. pylori infection. A total of 232 H. pylori-infected, treatment-naive patients were enrolled in this open-label, randomized controlled clinical trial. Patients were randomly allocated into 2 groups: the 14-day modified dual therapy group and the bismuth-containing quadruple therapy group. Eradication rates, drug-related adverse events, patient compliance, and drug costs were compared between the 2 groups. The modified dual therapy group achieved eradication rates of 87.9%, 91.1%, and 91.1% as determined by the intention-to-treat, per-protocol, and modified intention-to-treat analyses, respectively. The eradication rates were similar compared with the bismuth-containing quadruple therapy group: 89.7%, 91.2%, and 90.4%. In addition, modified dual therapy ameliorated variations in the CYP2C19, IL-1B-511, and H. pylori VacA genotypes. There were no significant differences in the compliance rates b...Continue Reading
References
Jan 1, 1989·Scandinavian Journal of Gastroenterology. Supplement·P UngeJ Olsson
Mar 1, 1996·Helicobacter·R W van der HulstG N Tytgat
Jun 14, 2001·Best Practice & Research. Clinical Gastroenterology·J Labenz
Jul 10, 2002·Gastroenterology·Takahisa FurutaHaruhiko Sugimurra
Sep 3, 2003·Helicobacter·Stephan MiehlkeEkkehard Bayerdörffer
Oct 8, 2004·Clinical Pharmacology and Therapeutics·Mitsushige SugimotoTakashi Ishizaki
Jul 4, 2006·Clinical Pharmacology and Therapeutics·Mitsushige SugimotoTakashi Ishizaki
Jan 12, 2007·Clinical Pharmacology and Therapeutics·T FurutaA Hishida
Jun 15, 2007·European Journal of Clinical Pharmacology·Naohito ShiraiTakahisa Furuta
Aug 3, 2007·Helicobacter·David Y GrahamYoshio Yamaoka
Mar 3, 2010·Journal of Gastroenterology·David Y GrahamAntone R Opekun
Jun 8, 2010·Gut·David Y Graham, Lori Fischbach
Oct 19, 2010·Gastroenterology Clinics of North America·Takahisa Furuta, David Y Graham
Jun 22, 2011·British Journal of Clinical Pharmacology·Seung Young KimJai Hyun Choi
Aug 14, 2012·Alimentary Pharmacology & Therapeutics·M SugimotoT Furuta
Apr 3, 2014·Helicobacter·Mitsushige SugimotoTakahisa Furuta
Apr 5, 2014·Helicobacter·Taraq A Attumi, David Y Graham
May 8, 2014·World Journal of Gastroenterology : WJG·Xi-Qing JiBo Yu
Sep 11, 2014·Journal of Digestive Diseases·Ling RenXiao Bo Li
Dec 3, 2014·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Jyh-Chin YangJau-Min Wong
Mar 7, 2015·Drugs·Karly P Garnock-Jones
Jun 25, 2015·Helicobacter·Liya ZhouSanren Lin
Jul 19, 2015·Gut·Kentaro SuganoUNKNOWN faculty members of Kyoto Global Consensus Conference
Sep 5, 2015·Gut·Wei ZhangHong Lu
Sep 16, 2015·Clinical Pharmacokinetics·Hirotoshi Echizen
Apr 15, 2016·Expert Review of Anti-infective Therapy·David Y Graham, Maria Pina Dore
Apr 24, 2016·The Journal of Antimicrobial Chemotherapy·Junbo HongNonghua Lu
Jun 2, 2016·Gastroenterology Research and Practice·Ran HanXiao-Ling Wu
Jul 15, 2016·Gastroenterology Research and Practice·WonGun KwackDavid Y Graham
Jul 30, 2016·The Lancet Global Health·Martyn PlummerSilvia Franceschi
Nov 2, 2016·Gut·P MalfertheinerUNKNOWN European Helicobacter and Microbiota Study Group and Consensus panel
May 4, 2017·Nature Reviews. Gastroenterology & Hepatology·Bich N Dang, David Y Graham
May 13, 2017·Alimentary Pharmacology & Therapeutics·Y S JungC H Park
Aug 7, 2017·The Lancet. Gastroenterology & Hepatology·Yu-Ting KuoUNKNOWN Asian Pacific Alliance on Helicobacter and Microbiota
Sep 25, 2017·Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association·Jia-Li HuDian-Chun Fang
Citations
Aug 23, 2019·Current Opinion in Gastroenterology·Erick A Argueta, Steven F Moss
Jan 14, 2020·Chinese Medical Journal·Yi HuNong-Hua Lu
Jan 10, 2020·Gut·Sho SuzukiKoichi Kawabe
May 20, 2020·Helicobacter·Laisheng LuoHong Lu
Jun 18, 2020·Helicobacter·Wen GaoHong Cheng
Sep 23, 2020·Expert Review of Gastroenterology & Hepatology·Jianwei YunDekui Zhang
Jul 16, 2020·Journal of Gastroenterology·Takuji GotodaHisatomo Ikehara
Dec 19, 2019·European Journal of Gastroenterology & Hepatology·Yi ZhangChun-Hui Lan
Apr 22, 2020·Helicobacter·Cai-Ping GaoHong Lu
Jul 28, 2020·Helicobacter·Alex Hwong-Ruey LeowKhean-Lee Goh
Sep 15, 2020·World Journal of Gastroenterology : WJG·Tian-Lian YanCheng-Fu Xu
Feb 6, 2020·Digestive Diseases and Sciences·Laisheng LuoHong Lu
Sep 2, 2020·Current Opinion in Gastroenterology·Erick A Argueta, Steven F Moss
Oct 12, 2020·Helicobacter·Zhiqiang SongZhanyue Niu
Nov 3, 2020·Expert Opinion on Pharmacotherapy·Sotirios Georgopoulos, Vasilios Papastergiou
Oct 29, 2020·Therapeutic Advances in Gastroenterology·Yang-Jie ZhuChun-Hui Lan
Mar 11, 2021·Journal of Gastroenterology and Hepatology·Chen QiaoYanqing Li
Jul 9, 2020·European Journal of Gastroenterology & Hepatology·Huimei XuDekui Zhang
May 19, 2021·Helicobacter·Cailing LiZhiqiang Song
Jun 3, 2021·Antibiotics·Vincenzo De FrancescoDino Vaira
Jul 16, 2021·Therapeutic Advances in Gastroenterology·Caiqi LiuTongsen Zheng
Jul 29, 2021·Helicobacter·Pei-Ying ZouChun-Hui Lan
Aug 17, 2021·Clinical and Translational Gastroenterology·Jing LiuXiu-Li Zuo
Oct 20, 2020·Journal of Clinical Gastroenterology·Qiuyue HuangXuezhi Zhang